dividual presented in our Grand Rounds, the upper limit of normal for pulmonary artery systolic pressure, assuming an estimated right atrial pressure of 5 mm Hg, is approximately 30 mm Hg, given his age (younger than 49 years) and body mass index (less than 25 [calculated as weight in kilograms divided by height in meters squared]).
1
In groups of individuals who are relatively young and nonobese, an upper limit of normal of 30 mm Hg for pulmonary artery systolic pressure (assuming a right atrial pressure of 5 mm Hg) is not too conservative. For example, in our cohort of patients with sickle cell disease followed up at the National Institutes of Health, the median age was 34 years and body mass index was 24. Similarly, in our group of individuals with human immunodeficiency virus infection followed up at the University of California San Francisco, the median age was 47 years and body mass index was 24.
Finally, in a study of patients with sickle cell disease, a tricuspid regurgitant jet velocity of 2.5 m/s or greater (which corresponds to a pulmonary artery systolic pressure of approximately 30 mm Hg) was strongly associated with an increased risk of death (rate ratio, 10.1; 95% confidence interval, 2.2-47.0; P Ͻ.001).
2 Therefore, in individuals with sickle cell disease, we believe that a pulmonary artery systolic pressure greater than 30 mm Hg should be considered abnormal. For patients with adverse advents, individual electronic charts were abstracted for additional data, including allergy history. Informal adjudication of the temporal relationship of nonfatal events with perflutren administration was performed. Nonfatal complications known to be attributable to stress testing (eg, transient atrial fibrillation during dobutamine infusion) were excluded. Adverse event frequencies were compared using Fisher exact test. A 95% confidence interval (CI) for all adverse events and an exact confidence limit for serious events (those requiring immediate physician attention) were calculated. Means were compared using t test. Statistical significance was defined by 2-sided PϽ.05. Analyses were performed using SAS version 9.1 (SAS Institute, Cary, North Carolina). The study (with waiver of consent) was approved by the Hennepin County Medical Center human subjects research committee.
Results. Perflutren was received by 16 025 patients ( 2) . There were no fatalities. Incidence of serious events was 0.031% (exact confidence limit, 0.01%-0.08%). Of patients with adverse events, 13 (65%) had a history of allergy and 13 (65%; P =.07) were women ( Table 2) .
Comment. Incidence of serious nonfatal reactions with perflutren was similar to that reported after low-osmolar iodinated radiocontrast media (0.04%), 3 and the potential risk factors of allergic history (higher prevalence than expected 4 ) and female sex have been linked to increased risk of serious radiocontrast reactions. 5 The most common adverse event was severe back pain.
Study limitations include potential underestimation of adverse event incidence due to incomplete registry ascertainment, occurrence more than 30 minutes after perflutren administration, or occurrence in sedated or unconscious patients. Conversely, because many patients receiving perflutren are seriously ill, some adverse events may not have been causally related to perflutren administration. 6 As a single-site study, the results may not be generalizable to all settings. Nevertheless, they suggest a relatively low rate of adverse events due to perflutren. 
